Results 241 to 250 of about 334,593 (294)

Congenital aleukemic leukemia cutis mimicking infantile hemangioma

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Ana Clara Maia Palhano   +5 more
wiley   +1 more source

AML-388: KDM6A Mutation in AML

Clinical Lymphoma Myeloma and Leukemia, 2020
Introduction Loss of KDM6A expression has been reported as a potential drug resistance mechanism in AML. Here, we describe the clinical characteristics and treatment outcomes in our cohort of AML patients with KDM6A mutations. Methods We annotated a cohort of 293 AML patients who were treated at our center between Jan 2016 and Dec 2019.
Vijendra Singh   +4 more
openaire   +1 more source

Reasons for treating secondary AML as de novo AML

European Journal of Haematology, 2010
AbstractIn a Danish bi‐regional registry‐based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML.
Ostgård, Lene Sofie Granfeldt   +8 more
openaire   +4 more sources

Immunotherapy of AML

2009
The applications of chemotherapy for the treatment of AML have been unchanged over the past three decades, with only 30% of patients demonstrating disease-free survival (DFS) [118]. Despite achieving CR following induction chemotherapy, the majority of patients relapse and succumb to their disease [6].
Gheath, Alatrash, Jeffrey J, Molldrem
openaire   +2 more sources

Epigenetics in AML

Best Practice & Research Clinical Haematology, 2010
Epigenetic regulation is known to affect gene expression, and recent research shows that aberrant DNA methylation patterning may play a role in leukemogenesis. All leukemias display aberrant distribution of cytosine methylation, which is most notably distributed in specific and distinct signatures in acute myeloid leukemia (AML).
openaire   +2 more sources

Secondary AML and AML-MRC

2020
Seongseok Yun   +2 more
openaire   +1 more source

AML

Oncology Times, 2015
openaire   +2 more sources

AML

Oncology Times, 2013
openaire   +2 more sources

Towards precision medicine for AML

Nature Reviews Clinical Oncology, 2021
Hartmut Döhner   +2 more
exaly  

Home - About - Disclaimer - Privacy